LEAWOOD, Kan., June 7, 2019 /PRNewswire/ -- Aratana
Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company
focused on the development and commercialization of innovative
therapeutics for dogs and cats, today announced the voting results
for the four proposals considered and voted upon by its
stockholders at its Annual Meeting on June
6, 2019. The Company reported 44,510,117 shares of common
stock present in person or represented by proxy at the Annual
Meeting, which represents approximately 91% of the Company's
outstanding common stock as of the April 10,
2019 record date.
The following are the voting results for the proposals, all of
which were described in the Company's Definitive Proxy Statement
filed with the Securities and Exchange Commission on April 19, 2019:
- Proposal 1: Elected all four Class III Directors until
the annual meeting of stockholders in 2022 and until their
respective successors have been duly elected and qualified,
including Craig A. Barbarosh, Esq.
(91.5% in favor; of shares voted), David L.
Brinkley (90.6%), Robert P. Roche,
Jr. (90.6%) and Craig A.
Tooman (94.2%)
- Proposal 2: Advisory vote of compensation paid to the
named executive officers of the Company, as disclosed in the
Company's Definitive Proxy Statement was approved (92% in favor; of
shares voted)
- Proposal 3: Advisory vote of the frequency of future
advisory votes for compensation paid to the named executive
officers of the Company was approved (94.7% for "One Year" or
annual frequency; of shares voted)
- Proposal 4: Ratification of the appointment of
PricewaterhouseCoopers LLP as the Company's independent registered
public accounting firm for the year ending December 31, 2019 (98%; of shares voted)
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on developing and commercializing
innovative therapeutics for dogs and cats. Our mission is to
successfully develop and deliver best-in-class therapeutics,
provide comprehensive service to veterinarians and serve as a
collaborator of choice for human and animal health companies. We
believe our therapeutics are highly differentiated, resolve
recognizable needs in compelling markets and have therapeutic
profiles superior to the standard of care. For more information,
please visit www.aratana.com.
Contacts
For investor inquires:
Rhonda Hellums
rhellums@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-reports-voting-results-from-2019-annual-meeting-of-stockholders-300864106.html
SOURCE Aratana Therapeutics, Inc.